{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:23:15Z","timestamp":1778617395853,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12376126"],"award-info":[{"award-number":["PNRR-MAD-2022-12376126"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12375634"],"award-info":[{"award-number":["PNRR-MAD-2022-12375634"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MCNT2\\u20132023-12378040"],"award-info":[{"award-number":["PNRR-MCNT2\\u20132023-12378040"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2022-PR-Single\/013"],"award-info":[{"award-number":["2022-PR-Single\/013"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PE00000006"],"award-info":[{"award-number":["PE00000006"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["CUP E65E24002260002"],"award-info":[{"award-number":["CUP E65E24002260002"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNC-E3\\u20132022\\u201323683267"],"award-info":[{"award-number":["PNC-E3\\u20132022\\u201323683267"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PE00000007"],"award-info":[{"award-number":["PE00000007"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["M6\/C2_CALL 2023"],"award-info":[{"award-number":["M6\/C2_CALL 2023"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007378","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007378","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022LNHZAP"],"award-info":[{"award-number":["2022LNHZAP"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["M6\/C2_CALL 2022"],"award-info":[{"award-number":["M6\/C2_CALL 2022"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["2022YMJXYT"],"award-info":[{"award-number":["2022YMJXYT"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["20225KH7BZ"],"award-info":[{"award-number":["20225KH7BZ"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["GR-2021-12373337"],"award-info":[{"award-number":["GR-2021-12373337"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clim.2026.110683","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:07:51Z","timestamp":1771315671000},"page":"110683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effect of dynamics and timing of SARS-CoV-2 vaccination on immune response in people with multiple sclerosis during cladribine treatment"],"prefix":"10.1016","volume":"284","author":[{"given":"Claudia","family":"Russo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clorinda","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fortunata","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Micillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"La Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giusy","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Di Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristyna","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Garziano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Perna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Zannella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Galdiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Franci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachele","family":"Bigi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmarco","family":"Abbadessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Procaccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Matarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110683_bb0005","author":"European Medicines A"},{"key":"10.1016\/j.clim.2026.110683_bb0010","author":"Food US, Drug A"},{"key":"10.1016\/j.clim.2026.110683_bb0015","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110683_bb0020","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clim.2026.110683_bb0025","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1006\/bbrc.1994.2337","article-title":"A novel effect of the new antileukemic drug, 2-chloro-2\u2032-deoxyadenosine, in human lymphocytes","volume":"203","author":"Sasv\u00e1ri-Sz\u00e9kely","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.clim.2026.110683_bb0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.clim.2026.110683_bb0035","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40120-023-00520-6","article-title":"Cladribine tablets mode of action, learning from the pandemic: a narrative review","volume":"12","author":"Carlini","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.clim.2026.110683_bb0040","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clim.2026.110683_bb0045","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2026.110683_bb0050","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.54.5.1145","article-title":"Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial","volume":"54","author":"Rice","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2026.110683_bb0055","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40263-018-0562-0","article-title":"Cladribine tablets: a review in relapsing MS","volume":"32","author":"Deeks","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clim.2026.110683_bb0060","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2026.110683_bb0065","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2026.110683_bb0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/cns.13034","article-title":"Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies","volume":"25","author":"Metze","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.clim.2026.110683_bb0075","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clim.2026.110683_bb0080","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1177\/1352458520971817","article-title":"COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments","volume":"27","author":"Laroni","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clim.2026.110683_bb0085","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2026.110683_bb0090","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s10072-021-05846-3","article-title":"Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis","volume":"43","author":"Hada","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.clim.2026.110683_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2026.110683_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.clim.2026.110683_bb0105","author":"Society MS"},{"key":"10.1016\/j.clim.2026.110683_bb0110","author":"Society MS"},{"key":"10.1016\/j.clim.2026.110683_bb0115","author":"National Multiple Sclerosis S"},{"key":"10.1016\/j.clim.2026.110683_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102452","article-title":"Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: two cases and implications for clinical practice","volume":"45","author":"De Angelis","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clim.2026.110683_bb0125","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110683_bb0130","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.metabol.2015.05.001","article-title":"Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate","volume":"64","author":"Carrieri","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.clim.2026.110683_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00527-21","article-title":"Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays","volume":"59","author":"Sholukh","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.clim.2026.110683_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103724","article-title":"Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod","volume":"60","author":"Capuano","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clim.2026.110683_bb0145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2026.110683_bb0150","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1177\/13524585221099413","article-title":"Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis","volume":"28","author":"Schmierer","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clim.2026.110683_bb0155","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clim.2026.110683_bb0160","doi-asserted-by":"crossref","DOI":"10.1177\/11795735211060118","article-title":"Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets","volume":"13","author":"Grothe","year":"2021","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.clim.2026.110683_bb0165","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clim.2026.110683_bb0170","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419854986","article-title":"Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers","volume":"12","author":"Stuve","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clim.2026.110683_bb0175","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200048","article-title":"Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of cladribine tablets: a MAGNIFY-MS substudy","volume":"10","author":"Wiendl","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clim.2026.110683_bb0180","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2174\/1570159X20666211217160451","article-title":"Vaccination opportunities in Multiple Sclerosis patients treated with cladribine tablets","volume":"20","author":"Moiola","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.clim.2026.110683_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103431","article-title":"Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis","volume":"57","author":"Spiezia","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clim.2026.110683_bb0190","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.clim.2026.110683_bb0195","unstructured":"Menactrims MENACTRIMS Practice Guideline for COVID-19 Vaccination in Patients with Multiple Sclerosis. n.d."},{"key":"10.1016\/j.clim.2026.110683_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1045101","article-title":"Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: lessons learnt a year in","volume":"13","author":"Pugliatti","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110683_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105134","article-title":"Frequency and risk factors of rebound after fingolimod discontinuation - a retrospective study","volume":"81","author":"Maunula","year":"2024","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:03:32Z","timestamp":1778616212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626000215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":41,"alternative-id":["S1521661626000215"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110683","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of dynamics and timing of SARS-CoV-2 vaccination on immune response in people with multiple sclerosis during cladribine treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110683"}}